サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1644162

患者マッチングのための人工知能ベースの臨床試験ソリューションの世界市場

Artificial Intelligence-based Clinical Trial Solutions for Patient Matching

出版日
ページ情報
英文 142 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
患者マッチングのための人工知能ベースの臨床試験ソリューションの世界市場
出版日: 2025年01月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 142 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

患者マッチングのための人工知能ベースの臨床試験ソリューションの世界市場は2030年までに24億米ドルに達する見込み

2024年に6億4,160万米ドルと推定される患者マッチングのための人工知能ベースの臨床試験ソリューションの世界市場は、分析期間2024-2030年にCAGR 24.8%で成長し、2030年には24億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである腫瘍学アプリケーションは、CAGR 25.3%を記録し、分析期間終了時には6億4,890万米ドルに達すると予測されます。代謝疾患アプリケーションセグメントの成長率は、分析期間中CAGR 24.5%と推定されます。

米国市場は1億6,870万米ドルと推定、中国はCAGR23.5％で成長予測

米国の患者マッチングのための人工知能ベースの臨床試験ソリューション市場は、2024年に1億6,870万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを23.5%として、2030年までに3億6,920万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ22.7%と21.4%と予測されています。欧州では、ドイツがCAGR約17.1%で成長すると予測されています。

世界の患者マッチングのための人工知能ベースの臨床試験ソリューション市場- 主要動向と促進要因まとめ

AIは臨床試験における患者マッチングにどのような革命をもたらしているか？

人工知能（AI）は、参加者確認のスピード、精度、効率を大幅に向上させることで、臨床試験における患者マッチングに変革をもたらしつつあります。臨床試験の患者をリクルートする従来の方法は、多くの場合時間がかかり、エラーや遅延が発生しやすい手作業プロセスに依存しています。AIベースのソリューションは、高度な機械学習アルゴリズムを活用して、電子カルテ（EHR）、遺伝子データベース、病歴から膨大な量の患者データを分析します。これらのアルゴリズムは、臨床試験の特定の基準を満たす適格な参加者を特定し、より的を絞った効果的な募集プロセスを保証します。

医師のメモや画像診断の結果などの非構造化データを処理するAIの能力は、患者マッチングにおけるもう一つの画期的な変化です。関連情報を抽出し、治験要件と照合することで、AIシステムは、他の方法では見落とされる可能性のある候補者を発見することができます。さらに、AIは治験プロトコルの進化に合わせて患者の適格性をダイナミックに更新することができ、一貫性のある最適化されたリクルートプロセスを保証します。この効率化により、治験の遅延が減少し、成功の可能性が高まるため、AIは治験のエコシステムにおいて不可欠な存在となっています。

臨床試験患者マッチングにおけるAI導入の原動力とは？

臨床試験の複雑化と個別化医療への需要の高まりが、患者マッチングにおけるAIベースのソリューションの採用を後押ししています。プレシジョン・メディシンが普及するにつれ、臨床試験には極めて特異的な遺伝的、人口統計学的、臨床的プロファイルを持つ参加者が必要とされます。AIは、大規模なデータセットをふるいにかけ、これらの正確な基準を満たす個人を特定することに優れており、現代の臨床研究における重要な課題に取り組んでいます。この能力は、適格な参加者を見つけることが特に困難な希少疾患の臨床試験において特に価値があります。

さらに、臨床試験のコストと期間が上昇していることから、製薬会社は効率性を向上させるためにAIを活用したソリューションの導入を促しています。患者募集は治験プロセスにおける大きなボトルネックであり、この段階での遅れは大きな財務的損失につながる可能性があります。AIはこのプロセスを合理化し、リクルートのタイムラインを短縮し、治験の迅速な進行を可能にします。ヘルスケアにおけるAIの利用に対する規制当局の支援は、データの相互運用性の向上と相まって、これらの技術の採用をさらに後押ししています。これらの要因は総体的に、臨床試験における患者マッチングの課題に対処する上でAIの重要性が高まっていることを浮き彫りにしています。

AIは臨床試験における公平性とアクセシビリティを改善できるか？

AIベースの臨床試験ソリューションは、臨床研究における公平性とアクセシビリティの向上に極めて重要な役割を果たしています。歴史的に、臨床試験における特定の人口統計学的集団の過少代表は重大な問題であり、偏った結果をもたらし、知見の一般化可能性を制限してきました。AIは、臨床試験の適格基準に合致する多様な患者集団を特定し、より広範な代表を確保することで、この課題に対処することができます。臨床情報と並行して社会人口統計学的データを分析することで、AIシステムは、現実の患者集団の多様性を反映した、より包括的な募集プロセスを促進することができます。

さらに、AIベースのプラットフォームは、遠隔地や分散型の試験モデルを可能にし、十分なサービスを受けていない地域や地理的に離れた地域の参加者へのアクセスを拡大します。このようなプラットフォームは、遠隔医療やモバイルヘルスソリューションを活用して患者を取り込み、治験実施施設への頻繁な移動の必要性を減らします。これは、移動が困難な人や専門ヘルスケア施設へのアクセスが困難な人にとって特に有益です。こうしたギャップを埋めることで、AIは臨床試験への参加を民主化し、包括性を促進し、医学研究の利益がより広く行き渡るようにしています。

何がAIベースの臨床試験ソリューション市場の成長を牽引しているのか？

患者マッチングのための人工知能ベースの臨床試験ソリューション市場の成長は、臨床研究の課題を克服するためのAIへの依存の高まりを反映した、いくつかの重要な要因によって牽引されています。臨床試験デザインの複雑化は、慢性疾患や希少疾患の蔓延と相まって、患者募集を効率化するAIソリューションの需要を促進しています。臨床試験の効率を高め、コストを削減するAIの能力も、製薬会社や医薬品開発業務受託機関（CRO）から多額の投資を集めています。

データ統合技術の進歩や、大規模で高品質なヘルスケアデータセットの利用可能性が高まっていることも、AI主導型ツールの採用をさらに後押ししています。ウェアラブル健康機器や患者ポータルの利用増加などの消費者行動動向は、患者マッチングに活用できる貴重なリアルタイムデータを生み出しています。臨床研究におけるイノベーションの促進を目的とした規制上の取り組みも、AIベースのソリューションの成長を後押ししています。これらの要因とAIアルゴリズムやクラウドコンピューティングの継続的な進歩が相まって、市場の急速な拡大が推進され、AIが臨床試験の将来における礎石として位置付けられています。

セグメント

用途（腫瘍学用途、代謝性疾患用途、神経疾患用途、感染症用途、循環器疾患用途、その他用途）、最終用途（製薬企業最終用途、学術機関最終用途、その他最終用途）

調査対象企業の例（注目の36社）

  • AmerisourceBergen Corporation
  • Antidote.me
  • ArisGlobal LLC
  • ConcertAI LLC
  • Deep 6 AI, Inc.
  • Mendel.ai
  • Microsoft Corporation
  • Paradigm Health, Inc.
  • Unlearn.Ai, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29240

Global Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market to Reach US$2.4 Billion by 2030

The global market for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching estimated at US$641.6 Million in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 24.8% over the analysis period 2024-2030. Oncology Application, one of the segments analyzed in the report, is expected to record a 25.3% CAGR and reach US$648.9 Million by the end of the analysis period. Growth in the Metabolic Diseases Application segment is estimated at 24.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.7 Million While China is Forecast to Grow at 23.5% CAGR

The Artificial Intelligence-based Clinical Trial Solutions for Patient Matching market in the U.S. is estimated at US$168.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$369.2 Million by the year 2030 trailing a CAGR of 23.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 22.7% and 21.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.1% CAGR.

Global Artificial Intelligence-Based Clinical Trial Solutions for Patient Matching Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing Patient Matching in Clinical Trials?

Artificial Intelligence (AI) is transforming patient matching in clinical trials by significantly improving the speed, accuracy, and efficiency of participant identification. Traditional methods of recruiting patients for clinical trials are often time-consuming and rely on manual processes that are prone to errors and delays. AI-based solutions leverage advanced machine learning algorithms to analyze vast amounts of patient data from electronic health records (EHRs), genetic databases, and medical histories. These algorithms identify eligible participants who meet the specific criteria for trials, ensuring a more targeted and effective recruitment process.

AI’s ability to process unstructured data, such as physician notes and imaging results, is another game-changer in patient matching. By extracting relevant information and cross-referencing it with trial requirements, AI systems can uncover candidates who might otherwise be overlooked. Furthermore, AI enables dynamic updates to patient eligibility as trial protocols evolve, ensuring a consistent and optimized recruitment process. This efficiency reduces trial delays and enhances the likelihood of success, making AI indispensable in the clinical trial ecosystem.

What Drives the Adoption of AI in Clinical Trial Patient Matching?

The increasing complexity of clinical trials and the growing demand for personalized medicine are driving the adoption of AI-based solutions in patient matching. As precision medicine gains traction, trials require participants with highly specific genetic, demographic, and clinical profiles. AI excels at sifting through large datasets to identify individuals who meet these precise criteria, addressing a critical challenge in modern clinical research. This capability is especially valuable for rare disease trials, where finding eligible participants can be particularly difficult.

Additionally, the rising cost and duration of clinical trials are prompting pharmaceutical companies to adopt AI-driven solutions to improve efficiency. Patient recruitment is a major bottleneck in the trial process, and delays in this phase can lead to significant financial losses. AI streamlines this process, reducing recruitment timelines and enabling trials to proceed faster. Regulatory support for the use of AI in healthcare, combined with advancements in data interoperability, is further boosting the adoption of these technologies. These factors collectively highlight the growing importance of AI in addressing the challenges of patient matching in clinical trials.

Can AI Improve Equity and Accessibility in Clinical Trials?

AI-based clinical trial solutions are playing a pivotal role in enhancing equity and accessibility in clinical research. Historically, underrepresentation of certain demographic groups in clinical trials has been a significant issue, leading to biased outcomes and limiting the generalizability of findings. AI can address this challenge by identifying diverse patient populations that align with trial eligibility criteria, ensuring broader representation. By analyzing socio-demographic data alongside clinical information, AI systems can facilitate more inclusive recruitment processes that reflect the diversity of real-world patient populations.

Moreover, AI-based platforms enable remote and decentralized trial models, expanding access to participants in underserved and geographically remote areas. These platforms leverage telehealth and mobile health solutions to engage patients, reducing the need for frequent travel to trial sites. This is particularly beneficial for individuals with limited mobility or access to specialized healthcare facilities. By bridging these gaps, AI is democratizing participation in clinical trials, fostering inclusivity and ensuring that the benefits of medical research are more widely distributed.

What’s Driving the Growth of the AI-Based Clinical Trial Solutions Market?

The growth in the Artificial Intelligence-Based Clinical Trial Solutions for Patient Matching market is driven by several critical factors, reflecting the increasing reliance on AI to overcome the challenges of clinical research. The escalating complexity of trial designs, coupled with the growing prevalence of chronic and rare diseases, is fueling demand for AI solutions that streamline patient recruitment. AI’s ability to enhance trial efficiency and reduce costs is also attracting significant investments from pharmaceutical companies and contract research organizations (CROs).

Advancements in data integration technologies and the increasing availability of large, high-quality healthcare datasets are further enabling the adoption of AI-driven tools. Consumer behavior trends, such as the increasing use of wearable health devices and patient portals, are generating valuable real-time data that can be leveraged for patient matching. Regulatory initiatives aimed at fostering innovation in clinical research are also supporting the growth of AI-based solutions. These factors, combined with continuous advancements in AI algorithms and cloud computing, are driving the market’s rapid expansion and positioning AI as a cornerstone in the future of clinical trials.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence-based Clinical Trial Solutions for Patient Matching market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application, Other Applications); End-Use (Pharmaceutical Companies End-Use, Academia End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • AmerisourceBergen Corporation
  • Antidote.me
  • ArisGlobal LLC
  • ConcertAI LLC
  • Deep 6 AI, Inc.
  • Mendel.ai
  • Microsoft Corporation
  • Paradigm Health, Inc.
  • Unlearn.Ai, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Economic Frontiers: Trends, Trials & Transformations
    • Artificial Intelligence-based Clinical Trial Solutions for Patient Matching - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AI-Powered Solutions Drive Market Growth by Improving Patient Recruitment Efficiency
    • Real-Time Data Integration in AI Platforms Expands Market Opportunities for CROs (Contract Research Organizations)
    • AI Solutions Spur Adoption for Diverse Patient Inclusion in Global Clinical Trials
    • Drug Development Pipelines Bode Well for Growth of AI in Accelerating Trial Timelines
    • AI-Driven Predictive Models Minimize Attrition Rates, Enhancing Trial Success
    • Demand for Cost Optimization Fuels AI Adoption in Clinical Trial Design
    • AI in Remote Monitoring of Trial Participants Creates New Opportunities for Decentralized Trials
    • AI Solutions for Early Disease Detection Propel Market Growth in Rare Disease Trials
    • AI in Mobile Health Devices Highlights Opportunities for Seamless Patient Data Collection
    • Big Pharma Embraces AI in Trial Feasibility Studies to Improve ROI
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Metabolic Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Metabolic Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Neurological Diseases or Conditions Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Neurological Diseases or Conditions Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Cardiovascular Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Academia End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Academia End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 34: China Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 36: China Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: China 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 42: Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 46: France Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: France 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 50: Germany Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Germany 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 54: Italy Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Italy 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 56: UK Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 58: UK Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: UK 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence-based Clinical Trial Solutions for Patient Matching Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 68: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of World 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by Application - Percentage Breakdown of Value Sales for Oncology Application, Metabolic Diseases Application, Neurological Diseases or Conditions Application, Infectious Diseases Application, Cardiovascular Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 70: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Rest of World 6-Year Perspective for Artificial Intelligence-based Clinical Trial Solutions for Patient Matching by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical Companies End-Use, Academia End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION